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The FORWARD study is a randomised, double-blind trial that compares the efficacy and safety
of 48 weeks treatment with extrafine beclomethasone dipropionate/formoterol fumarate
(BDP/FOR), 100/6 mg pMDI, 2 inhalations BID, vs. FOR 12 mg pMDI, 1 inhalation BID, in severe
COPD patients with a history of exacerbations. Co-primary endpoints were exacerbation rate
over 48 weeks and pre-dose morning FEV1 at 12 weeks.
The ITT population included 1186 patients (69% males, mean age 64 years) with severe
airflow limitation (mean post-bronchodilator FEV1 42% predicted). Salbutamol as rescue ther-
apy, theophylline and tiotropium (if stable regimen prior to screening) were allowed.
Compared to FOR, BDP/FOR: (1) reduced the exacerbation rate (rate ratio: 0.72 [95% confi-
dence interval 0.62e0.84], p < 0.001); (2) improved pre-dose morning FEV1 (mean difference:art and Lung Institute, Imperial College London, London, United Kingdom.
erial.ac.uk, w.wedzicha@imperial.ac.uk (J.A. Wedzicha).
Trial to Reduce Exacerbations in COPD (FORWARD) trial are listed in the on-line supplement.
4.05.013
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/3.0/).
1154 J.A. Wedzicha et al.0.069 L [0.043e0.095] p < 0.001); (3) prolonged the time to first exacerbation; (4) improved
the SGRQ total score. The percentage of patients with adverse events was similar (52.1% with
BDP/FOR and 49.2% with FOR). Pneumonia incidence was low, slightly higher with BDP/FOR
(3.8%) than with FOR (1.8%). No difference for laboratory values, ECG or vital signs.
Extrafine BDP/FOR significantly reduces the exacerbation rate and improves lung function of
patients with severe COPD and history of exacerbations as compared to FOR alone.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Chronic obstructive pulmonary disease (COPD) is a major
public health problem that imposes considerable economic
and healthcare burdens on society, with the disease being
projected to be the third leading cause of morbidity and
mortality worldwide by 2030 [1].
Current pharmacological treatment reduces symptoms
of the disease, improves lung function and prevents exac-
erbations, the latter being an important outcome in COPD
that affects disease progression [2].
A combination of beclomethasone dipropionate/for-
moterol fumarate (BDP/FOR) has been developed in a
pressurized metered dose inhaler (pMDI) device delivering
extrafine particles which enable the drug to reach also the
small airways, a relevant site of inflammation in COPD, and
have, therefore, the potential to improve therapeutic ef-
ficacy [3]. Recent evidence showed that, in patients with
severe COPD, the use of BDP/FOR for 48 weeks improved
FEV1 to the same degree as budesonide/FOR with a nominal
dose of BDP two-fold lower than the equipotent daily dose
of budesonide; however, in this study, no combination
showed reduction of COPD exacerbations compared to FOR
alone [4]. The most likely explanation for this finding is that
the population enrolled had a low rate of exacerbations,
due in part to the study design which required patients to
be stable at enrolment and therefore less likely to exac-
erbate during the study. Further investigations were
therefore needed to assess the potential benefit of BDP/
FOR on exacerbation rates in patients with frequent
exacerbations.
To better understand the effects of BDP/FOR on the
prevention of COPD exacerbations, a double-blind, rando-
mised, controlled study was designed in severe COPD pa-
tients with a documented history of exacerbations [5].
Previous history of exacerbations is the best predictor for
future exacerbation [6], but since exacerbations are often
not reported by patients [7e9], two innovative aspects
were implemented in the study. Firstly, we used an elec-
tronic real-time transmission of EXACT diary data to
enhance contact between patients and physicians and to
improve the reporting of exacerbations. Secondly, by
coordinating recruitment waves in the northern and
southern hemispheres, different winter exacerbation peaks
were captured across the globe, thus increasing the chance
of catching winter respiratory viral infections. The primary
aim of the study was to test the superiority of extrafine
BDP/FOR 100/6 mg, 2 inhalations BID over extrafine FORalone 12 mg, 1 inhalation BID in both the reduction of ex-
acerbations and the improvement of pre-dose morning FEV1
in COPD patients.
Methods
The on-line supplement presents an extended and detailed
version of the methodology used in the FORWARD study. A
summary is shown below.
Study participants and ethics
Eligible patients were outpatients, aged >40 years, current
or former smokers (10 pack-years) with a diagnosis of
severe COPD (post-pMDI salbutamol FEV1/FVC <0.7 and 30%
FEV1 <50% of predicted normal value) and a documented
history of at least one exacerbation in the previous year.
Patients were not eligible in case of asthma diagnosis and
other unstable concurrent diseases, which might have
affected the feasibility of the results according to in-
vestigator’s judgement.
The study, approved by an institutional review board for
each of the clinical sites, was conducted in accordance with
the Declaration of Helsinki, Good Clinical Practice, and
applicable local regulations. All participants signed the
informed consent.
Study design
The FORWARD study was a phase III, double-blind, rand-
omised, 2-arm parallel-group study that compares the
efficacy and tolerability of BDP/FOR 100/6 mg, 2 in-
halations BID, vs. FOR 12 mg, 1 inhalation BID, both
administered using a pMDI over 48 weeks [5]. Inhalers
were identical for BDP/FOR and FOR alone and blinding on
the 2 vs. 1 inhalation b.i.d for FOR was guaranteed by
providing 2 inhalers to each patient (one for each inha-
lation), the second inhaler containing placebo for those
patients randomised to receive FOR alone. After a 2-week
run-in period under FOR 12 mg BID, patients were centrally
randomised stratifying by country and smoking status.
Visits were planned at 4, 12, 24, 36 and 48 weeks after
randomisation. Theophylline and Tiotropium were
allowed during the study if the dose was stable before
screening and maintained constant throughout the study,
salbutamol was allowed per rescue use. Electronic diaries
were used daily to record treatment intake, use of rescue
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tionnaire [10].
Seasonal recruitment
Because COPD exacerbations peak during winter, patient
recruitment was initiated before the end of winter in three
waves across the globe to capture more winter-related
exacerbations: two in the Northern (waves 1 and 3) and one
in the Southern Hemisphere (wave 2). The recruitment was
from 02/10/2009 to 22/12/2009 and from 05/10/2010 to
17/02/2011 (waves 1 and 3 respectively); from 30/04/2010
to 12/02/2011 (wave 2).
Efficacy endpoints
The two co-primary efficacy endpoints of the study were:
COPD exacerbation rate over the entire treatment period
and change in pre-dose morning FEV1 (L) from baseline
(randomisation visit) to Week 12.
Secondary efficacy endpoints included; time to first
COPD exacerbation, change from baseline in pre-dose
morning FEV1 at other visits and health status as assessed
by St. George’s Respiratory Questionnaire (SGRQ) total
score at the end of the treatment.
Safety endpoints
Safety evaluation included adverse events (AEs), serious
AEs (SAEs), vital signs, laboratory data (haematology and
chemistry), and 12-lead electrocardiograms (ECGs). Labo-
ratory tests and ECGs were performed at screening and at
Week 48 (or at early discontinuation).
Measurements
COPD exacerbations were defined according to GOLD
guideline definition [11] and their recognition was
enhanced by daily EXACT diary data transmission, although
patients were allowed to seek medical advice directly, if
needed. The EXACT, a 14-item questionnaire [10], was used
to alert the physician about patients’ symptom worsening
but not to diagnose the exacerbation per se e that was
performed on a clinical basis by the physician. The patient
received regular reminders to contact the physician in case
of symptoms worsening.
Spirometry was performed at each visit, following in-
ternational recommendations [12], at approximately the
same time of day and using the same spirometer throughout
the course of the study. At screening, to verify the eligi-
bility of the patient, spirometry was performed before and
after the inhalation of 400 mg salbutamol (4  100 mg pMDI,
ventolin). At each clinical visits (from randomisation to
Week 48), spirometry assessments were carried out prior to
study drug administration and 2 h after dosing. Rescue
medication (salbutamol) was withheld for at least 8 h and
tiotropium for at least 72 h prior to the pre-dose assessment
at each visit.
Health status was assessed at randomisation and Week
48 (or at early discontinuation) using the SGRQ [13].Statistical analysis
551 randomised patients per group provided 82.6% power to
detect a 20% reduction in exacerbation rate, assuming an
annual rate of 0.8 with FOR, an overdispersion of 1.1 and
13.5% of patients discontinued at the end of study. 530
evaluable patients per group at Week 12 provided 80%
power to detect a mean difference of 50 ml in pre-dose
morning FEV1 assuming an SD of 290 ml [5].
Efficacy variables were analysed on the Intent-to-Treat
(ITT) population (all patients with efficacy data), while
safety analysis included all treated patients. The number of
COPD exacerbations was submitted to a Poisson regression
model allowing for overdispersion and including country,
smoking status, tiotropium use, number of exacerbations in
the last year and post-salbutamol FEV1 at Visit 1 as cova-
riates. Pre-dose morning FEV1 was analysed using a mixed
model for repeated measures (MMRM) including country,
smoking status, tiotropium use and the baseline value as
covariates. Analyses of the primary variables were also
performed on the Per Protocol (PP) population (ITT patients
with no major deviations) stratifying by tiotropium use,
smoking status and gender. A post-hoc sensitivity analysis of
the exacerbations based on the negative binomial model
was conducted [14]. The analysis of the average FEV1 over
the entire treatment period was also based on the MMRM
above described, assuming equal weight for each visit.
Time to first exacerbation was analysed using a Cox pro-
portional hazards model including the same covariates of
the Poisson regression. The SGRQ total score was submitted
to an ANCOVA model including the same covariates
considered in the analysis of FEV1. All statistical analyses
were performed using SAS version 9.2 (SAS Institute, Cary,
NC, USA).
Results
Patient characteristics at baseline
Fig. 1 presents the flow diagram of the study. A total of
1693 patients were screened, of whom 1199 were rando-
mised to BDP/FOR (NZ 602) or FOR (NZ 597) groups. The
most common reasons for screen failure were failure to
meet inclusion criteria and consent withdrawal (n Z 362
and n Z 108, respectively). The most common reason for
early study discontinuation in both treatment groups was
withdrawal of consent (4.2% and 6.0% in the BDP/FOR and
FOR groups, respectively). A total of 7 randomised patients
in the BDP/FOR group and 6 in the FOR group were not
included in the ITT population due to the following reasons:
violation of a major entry criterion (patients without COPD,
n Z 5 in the BDP/FOR group and n Z 4 in the FOR group),
lack of post-baseline efficacy data (n Z 1 in each group)
and no intake of study drug (n Z 1 in each group, these
patients were also not included in the analysis of safety).
Table 1 shows that the treatment groups were well-
matched for demographic and functional characteristics
at baseline. About 39% of the patients were current
smokers, with a mean cumulative smoking exposure slightly
above 40 pack-years. On average, about 1.5 exacerbations/
year in the previous 12 months were reported in both
Figure 1 Flow diagram of the study.
1156 J.A. Wedzicha et al.groups and the mean SGRQ total score was approximately
48. Mean post-salbutamol FEV1 at screening was 42% of the
predicted value.
Efficacy endpoints
COPD exacerbation rate
The percentage of patients with exacerbations was lower in
the BDP/FOR group (44.4%) than in the FOR group (49.7%,
Table 2). The adjusted rate of exacerbations per patient per
year was lower in the BDP/FOR arm (0.80 vs. 1.12), leading
to a statistically significant adjusted rate ratio between the
two treatment groups in favour of BDP/FOR of 0.72 (95% CI:
0.62, 0.84; p < 0.001) (Table 2), that corresponds to a 28%
reduction in the exacerbation rate with BDP/FOR. These
results were confirmed in the PP population and in thestratified analysis of themales, current smokers, ex-smokers
and tiotropium and nonetiotropium users at randomisation.
In female patients, a trend toward a lower exacerbation rate
with BDP/FOR compared to FOR was found but did not reach
statistical significance (Fig. 2). Consistent results were
provided by the post-hoc sensitivity analysis using the
negative binomial model.
Change in pre-dose morning FEV1 from baseline to Week
12
The adjusted mean FEV1 change at Week 12 was larger in
the BDP/FOR group than in the FOR group (0.081 L vs.
0.012 L), with a statistically significant difference between
treatment groups in favour of BDP/FOR (0.069 L [95% CI:
0.043, 0.095]; p < 0.001) (Table 2). This was confirmed in
the PP population and in all subgroups analyzed (Fig. 3).
Table 1 Demographic and baseline clinical characteristics
of patients (ITT population).
BDP/FOR
(N Z 595)
FOR
(N Z 595)
Males, n (%) 408 (69%) 410 (69%)
Age, years, mean  SD 64.6  8.6 63.9  8.6
BMI, Kg/m2, mean  SD 26.5  5.4 26.5  5.3
Current smokers, n (%) 231 (39%) 237 (40%)
Packs/year, mean  SD 43.1  23.5 42.7  22.9
SGRQ total score, mean  SD 47.3  17.9 48.0  17.2
Number of exacerbations in
past year, mean  SD
1.5  0.9 1.4  0.9
Tiotropium users, n (%) 318 (53%) 298 (50%)
Post-bronchodilator FEV1,
% of predicted, mean  SD
41.9  6.0 41.6  6.0
Post-bronchodilator FEV1,
L, mean  SD
1.15  0.30 1.16  0.30
Post-bronchodilator
FEV1/FVC, mean  SD
0.48  0.10 0.48  0.10
Reversibility, L, mean  SD 0.10  0.12 0.10  0.13
Reversibility, %, mean  SD 10.8  12.9 10.7  14.1
Note: lung function data are from Visit 1 (screening visit).
Reversibility in L was calculated as post-bronchodilator FEV1
minus pre-bronchodilator FEV1, while reversibility in percent-
age was calculated as (reversibility in L/pre-bronchodilator
FEV1)*100.
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Analysis of time to first COPD exacerbation showed a
significantly lower even risk in the BDP/FOR group
compared to the FOR group, with a hazard ratio of 0.80
(95% CI: 0.68, 0.95; p Z 0.010) (Fig. 4).Table 2 COPD exacerbations during the study: change from bas
of treatment in the SGRQ total score.
ITT population
BDP/FOR
N Z 595
F
N
COPD exacerbations during the study
Number (%) of patients with at
least one exacerbation
264 (44.4%) 2
Adjusted rate per patient per
year (95% CI)
0.804 (0.713, 0.907) 1
(
Adjusted rate ratio BDP/FOR
vs. FOR (95% CI)
0.719 (0.619, 0.837)
p < 0.001
Change from baseline to Week 12 in FEV1 (L)
Adjusted mean change
from baseline (95% CI)
0.081 (0.062, 0.100)
p < 0.001
0
(
p
Adjusted mean difference BDP/
FOR vs. FOR (95% CI)
0.069 (0.043, 0.095)
p < 0.001
Change from baseline to the end of treatment in the SGRQ tot
Adjusted mean change from
baseline (95% CI)
3.55 (4.80, 2.29)
p < 0.001

(
p
Adjusted mean difference BDP/
FOR vs. FOR (95% CI)
2.78 (4.51, 1.05)
p Z 0.002Fig. 5 presents the adjusted mean change from baseline
in pre-dose morning FEV1 at all post-randomisation visits.
Differences between groups were statistically significant in
favour of BDP/FOR at all visits. The average FEV1 change
over the treatment period was also significantly higher in
the BDP/FOR arm (adjusted mean difference between
treatments: 0.062 L [95% CI: 0.040, 0.084]; p < 0.001).
Likewise, the decrease (i.e. improvement) from baseline
to end of treatment in the SGRQ total score was statistically
significant only in the BDP/FOR group (p < 0.001), and the
adjusted mean difference of 2.78 units (95%: 4.51,
1.05) between treatments was statistically significant
(p Z 0.002) (Table 2).
Safety endpoints
The incidence of AEs, SAEs, adverse drug reactions (ADRs)
and withdrawals due to AEs were similar in the two treat-
ment groups (Table 3). Pneumonia was reported by 23 pa-
tients (3.8%) in the BDP/FOR group and 11 patients (1.8%) in
the FOR group (Table 4).
Treatment-emergent SAEs and ADRs are listed in on-line
supplement (Table 5). The most commonly reported ADR
was oral candidiasis (2.2% and 0.3% respectively in the BDP/
FOR and FOR groups). Two ADRs (1 in each treatment arm)
were considered serious (atrial fibrillation), a known AE
associated with FOR treatment (Table 5 on-line supple-
ment). Changes in vital signs and 12-lead ECG did not raise
any unexpected safety concern. Eleven patients (1.8%) in
the BDP/FOR group and 8 patients (1.3%) in the FOR group
died. Four out of the 11 patients’ deaths in the BDP/FOR
group were due to events started after treatment discon-
tinuation. None of the deaths reported during the trial were
classified as related to the study treatment.eline to Week 12 in FEV1 and change from baseline to the end
PP population
OR
Z 591
BDP/FOR
N Z 517
FOR
N Z 515
94 (49.7%) 222 (42.9%) 257 (49.9%)
.118
1.006, 1.242)
0.774 (0.679, 0.881) 1.073
(0.959, 1.200)
0.721 (0.613, 0.848)
p < 0.001
.012
0.007, 0.030)
Z 0.218
0.080 (0.060, 0.100)
p < 0.001
0.015
(0.005, 0.035)
p Z 0.152
0.065 (0.037, 0.093)
p < 0.001
al score
0.77
2.01, 0.47)
Z 0.222
e e
e e
Figure 2 Summary of the analyses of COPD exacerbations during the study. Legend: Bars represent the 95% CI.
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The result of the FORWARD study shows that, compared to
FOR, BDP/FOR significantly reduces the exacerbation rate
and improves lung function in patients with severe COPD
and history of exacerbations. This data further confirms the
beneficial effects of ICS combined to a bronchodilator in
preventing exacerbations in COPD patients. Moreover, the
exacerbation rate in the BDP/FOR group was reduced
regardless of whether patients were receiving chronically
tiotropium, suggesting that the effects on preventingFigure 3 Summary of the analyses of change in pre-dose morning
95% CI.exacerbations is independent from other bronchodilation
background therapy.
In this study both co-primary endpoints were met: (1)
compared to FOR, BDP/FOR reduced the adjusted exacer-
bation rate ratio by 28%. This reduction compares favour-
ably with that estimated by a recent systematic meta-
analysis for the effects of an ICS/LABA combination vs.
LABA alone (24%) [15]; and, (2) the pre-dose morning FEV1
increase from baseline to Week 12 was significantly larger
in the BDP/FOR group. This improvement in FEV1 was found
in patients who were both tiotropium and non-tiotropiumFEV1 (L) from baseline to Week 12. Legend: Bars represent the
Figure 4 KaplaneMeier plot of time to first COPD exacer-
bation (ITT population).
Figure 5 Adjusted mean change from baseline in pre-dose
morning FEV1 (L) (ITT population). Legend: Bars represent
95% CI. Asterisk indicate a statistically significant difference
(p < 0.05) between treatment groups.
Extrafine beclomethasone/formoterol in severe COPD patients 1159users at randomisation (adjusted mean differences found of
48 and 90 ml, respectively). Prior studies of twice-daily ICS/
LABA combinations have shown a significant improvement
of the combination over the LABA component alone for pre-Table 3 Summary of treatment-emergent adverse events (safe
BDP/FOR
N Z 601
Number of patients (%) Number
Adverse events 313 (52.1) 903
Serious adverse events 106 (17.6) 189
Adverse drug reactions
(ADRs)
42 (7.0) 49
Serious ADRs 1 (0.2) 1
Severe adverse events 75 (12.5) 115
Adverse events leading
to discontinuation
26 (4.3) 30
Adverse events leading
to death
11 (1.8) 14dose morning FEV1 of about 50 ml at 3 months [16e18].
These results were confirmed in other clinically relevant
subgroups such as current smokers and ex-smokers,
although women had a smaller difference in exacerbation
rate between treatments compared to men. This might be
due, at least partially, to the greater proportion of current
smokers in women (45%) than in men (37%), as active
smoking reduces the sensitivity to steroids [19]. The effects
on lung function and COPD exacerbations were also asso-
ciated with an improvement in health status as measured
by the SGRQ. This is expected as changes in COPD exacer-
bation rates are closely related to changes in health status
[7,20]. SGRQ changes did not reach the MCID and this could
be due to the long study duration, since the largest SGRQ
effect, compared with placebo, occurs at around 6 months
with long-acting bronchodilators and, subsequently,
improvement in SGRQ, scores may subsequently return to
the baseline level (or worse) due to disease progression.
The results confirm that ICS/LABA combination therapy
is more effecting in reducing exacerbation in severe COPD
patients over LABA alone; this demonstrates the anti-
inflammatory effect of ICS, suggesting also a complemen-
tary and synergistic interaction at the molecular level.
This study also had a number of novel methodological
approaches to enhance exacerbation reporting. Many
studies of exacerbation therapy have reported lower
exacerbation rates than expected even though patients
have been enriched for an exacerbation history [21e23]. A
previous study evaluating exacerbation rates with BDP/FOR
compared to FOR was not able to show a difference be-
tween treatments, but there was a very low rate of exac-
erbations in the study population, despite the subjects to
be enrolled were required to have at least one exacerba-
tion in the previous year [4]. The current study took a
number of steps to avoid such an occurrence. COPD exac-
erbations have been shown to peak in incidence during the
winter season [24,25] and thus patient recruitment was
initiated before the end of winter in three waves across the
globe to optimally capture exacerbations, two in the
Northern (waves 1 and 3) and one in the Southern Hemi-
sphere (wave 2). COPD exacerbations that occur during the
winter months are more likely to have a viral aetiology and
have been shown to be longer in duration [24e27] and thusty population).
FOR
N Z 596
of events Number of patients (%) Number of events
293 (49.2) 840
94 (15.8) 158
26 (4.4) 37
1 (0.2) 1
62 (10.4) 94
28 (4.7) 38
8 (1.3) 10
Table 4 Treatment-emergent adverse events reported in 1% of patients in any treatment group (safety population).
BDP/FOR
N Z 601
FOR
N Z 596
Number of
patients (%)
Number
of events
Number of
patients (%)
Number
of events
Infections and infestations
Nasopharyngitis 17 (2.8) 21 21 (3.5) 24
Pneumonia 23 (3.8) 26 11 (1.8) 11
Bronchopneumonia 3 (0.5) 3 1 (0.2) 1
Lobar pneumonia 1 (0.2) 1 0 0
Pneumonia 19 (3.2) 22 10 (1.7) 10
Upper respiratory tract infection 17 (2.8) 17 13 (2.2) 15
Oral candidiasis 18 (3.0) 22 4 (0.7) 5
Pharyngitis 11 (1.8) 13 7 (1.2) 7
Influenza 8 (1.3) 8 7 (1.2) 8
Lower respiratory tract infection 9 (1.5) 10 4 (0.7) 5
Urinary tract infection 11 (1.8) 14 2 (0.3) 2
Gastroenteritis 5 (0.8) 5 6 (1.0) 6
Sinusitis 6 (1.0) 6 0 0
Respiratory, thoracic and mediastinal disordersa
Dyspnoea 9 (1.5) 11 19 (3.2) 23
Cough 5 (0.8) 6 15 (2.5) 16
Gastrointestinal disorders
Diarrhoea 8 (1.3) 9 11 (1.8) 11
Constipation 8 (1.3) 9 6 (1.0) 6
Gastritis 5 (0.8) 5 8 (1.3) 9
Nausea 2 (0.3) 2 6 (1.0) 7
Musculoskeletal and connective tissue disorders
Back pain 12 (2.0) 13 16 (2.7) 18
Arthralgia 9 (1.5) 9 7 (1.2) 7
Muscle spasms 11 (1.8) 12 3 (0.5) 3
Vascular disorders
Hypertension 26 (4.3) 26 27 (4.5) 28
Metabolism and nutrition disorders
Hyperglycaemia 7 (1.2) 7 6 (1.0) 6
Hypercholesterolemia 6 (1.0) 6 6 (1.0) 6
Cardiac disorders
Cardiac failure 11 (1.8) 13 6 (1.0) 7
Atrial fibrillation 7 (1.2) 7 2 (0.3) 3
Nervous system disorders
Headache 10 (1.7) 11 12 (2.0) 13
General disorders and administration site conditions
Chest pain 7 (1.2) 8 9 (1.5) 9
Oedema peripheral 3 (0.5) 3 11 (1.8) 12
Investigations
Gamma-glutamyltransferase increased 2 (0.3) 2 7 (1.2) 7
Weight decreased 2 (0.3) 2 6 (1.0) 6
Psychiatric disorders
Insomnia 8 (1.3) 8 10 (1.7) 14
Skin and subcutaneous tissue disorders
Dermatitis 9 (1.5) 9 2 (0.3) 2
Reproductive system and breast disorders
Benign prostatic hyperplasia 6 (1.0) 6 5 (0.8) 5
a COPD exacerbation are not listed, described in Table 2.
1160 J.A. Wedzicha et al.associated with increased airway and systemic inflamma-
tion and thus more likely to be reduced in severity and
frequency by anti-inflammatory therapy. Thus by recruiting
patients in waves before the winter season ends,exacerbations will be more commonly detected early in the
course of the study and before patient withdrawals from
the study are observed the most, potentially enhancing the
exacerbation rate.
Extrafine beclomethasone/formoterol in severe COPD patients 1161The second technique was a novel application of the
EXACT diary, using telemonitoring, to raise the awareness of
physician to the possibility that an exacerbation may have
been occurring. In this study the standard healthcare
resource use definition of a COPD exacerbation was used,
however it is known that COPD patients often under report
their exacerbations and over 50% of exacerbation events
may be unreported [7,9]. It is also recognised that unre-
ported exacerbations may also affect health status and thus
patients must be encouraged to treat these events [8,25]. In
this study, the EXACT daily diary was administered using the
Blackberry mobile device as an aid to detection of events
[26]. There was very good compliance with e-diary comple-
tion (mean compliance 90.7% in BDP/FOR and 90% in FOR
group). When the pre-specified criteria for symptoms’
worsening were met [10], an alert was generated that a
possible exacerbation had occurred prompting early patient
reporting. Early reporting of exacerbations will lead to more
homogeneous exacerbation events especially as airway in-
flammatory changes during COPD exacerbations occur early
in the time course of these events. This study showed that
the EXACT can be used to aid detection, but despite this,
only 47% of patients with severe COPD and an exacerbation
history reported an exacerbation over the 48 week study
period. Further analyses of the EXACT diaries from this study
will be reported in due course, although as an exploratory
outcome. Two novel methodological approaches were used
in this study; recruiting before the winter months and using a
COPD diary to increase exacerbation reporting rates. Thus
this study will also inform future trials of exacerbation pre-
ventative therapies in COPD.
The most common adverse drug reaction that was re-
ported during the study period was oral candidiasis, which
was not unexpected because of the presence of the ICS in
the combination therapy [15]. The BDP/FOR treatment arm
was also associated with a higher incidence of pneumonia.
This is in line with recent studies [22,28e30], showing a 2e3
fold excess of pneumonia in the ICS/LABA treatment arms
of studies compared to the corresponding monotherapy.
However although there is an increased risk of pneumonia
with BDP/FOR therapy, the number of pneumonia events
relative to the number of exacerbations during the study
was small and consistent with previous observations sug-
gesting that the benefit of an ICS/LABA combination out-
weighs the potential risks.
In conclusion, the results of the FORWARD study show
that BDP/FOR is superior to FOR in the reduction of COPD
exacerbations and improvement in pre-dose morning FEV1
as well as for the symptom-based parameters, thus sup-
porting the positioning of BDP/FOR among the appropriate
therapeutic options for this category of patients.Funding
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